Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Suono Bio is raising $13,737,249.00 in new funding. Sources indicate as part of senior management President, Carl Schoellhammer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Suono Bio

Suono Bio is a biotechnology company harnessing our proprietary delivery platform to transform treatment of intractable diseases. Suono Bio is developing therapeutic products for inflammatory-mediated diseases leveraging their ultra-rapid and formulation independent delivery technology. Suono Bio’s platform enables rapid, localized delivery of small molecules, biologics, and nucleic acids and gene therapies without the need for encapsulation of the therapeutic. Suono Bio is on a mission to revolutionize what therapeutics may be used to treat diseases. Advances in genomics have enabled a step-shift in our understanding of diseases and relevant targets to treat those diseases but delivery technologies lag. Our technology promises to deliver potentially superior therapies, like nucleic acids and gene therapies, in a simplified proprietary formulation. Suono Bio’s mission is to enable the use of the right drug at the right location in the right patient.

To learn more about Suono Bio, visit http://www.suonobio.com/

Contact:
Carl Schoellhammer, President
617-299-1496
https://www.linkedin.com/in/carl-schoellhammer-728bb15/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved